Patients with acute leukemia who are treated with common therapy have increased risk for heart failure
Patients with acute lymphoblastic leukemia or acute myeloid leukemia who are treated with anthracyclines are at a heightened risk of heart failure—most often within one year of exposure to the chemotherapy treatment, according to a new study led by researchers at Penn Medicine.
FULL STORY AT Penn Medicine News →